We develop extracorporeal diagnostic agents to quantify trace molecular biomarkers expressed by tumor cells or disease cells in the blood. These diagnostics will allow doctors to assess a patients’ likelihood of responding to a given therapy or monitor the progression of a patients’ disease state, thereby facilitating a more precise and effective choice from the available therapeutic options. We look at disease as a process from preservation through diagnostication, prognosis, and treatment rather than a state, and we will realize such “Theranostics”, as a new approach to disease management.
A vascular inflammation marker, Pentraxin 3 (PTX3/TSG-14)
Pentraxin 3 appears to be an excellent predicative biomarker for acute coronary syndrome.
Perseus Proteomics have established a high sensitivity PTX3 detection method(*1), which we expect to be a breakthrough biomarker capable of predicting patients' risk of atherosclerosis in the earliest stages.
We start selling PTX3 ELISA System “Human Pentraxin3/TSG-14 ELISA System” for research use.